Betta Pharmaceuticals Co., Ltd.

Betta Pharmaceuticals Co., Ltd. is a national-level high-tech pharmaceutical company based in China, specializing in the research and development, manufacturing, sales, and marketing of innovative drugs. Founded by a team of PhD returnees, the company emphasizes the development of oncology therapies that address unmet medical needs, particularly in lung cancer and other significant cancer indications. Betta Pharmaceuticals was listed on the ChiNext board of the Shenzhen Stock Exchange in 2016. The company has launched five therapies and has built a robust pipeline focused on various malignant cancers, including non-small cell lung cancer (NSCLC), renal, and breast cancers. Betta's notable products include Icotinib hydrochloride (Conmana®), Ensartinib hydrochloride (Ensacove®), and the third-generation EGFR-TKI Befotertinib (Surmana®), among others. With a commitment to independent research and strategic collaborations, Betta Pharmaceuticals aims to advance its innovative drug commercialization platform and expand its presence in the biopharmaceutical industry.

1. Leading lung cancer drug franchise with fully-integrated capabilities and product portfolio consisting of five successfully commercialized products and numerous innovative drug candidates 2. One of the first few innovative biopharmaceutical companies in China with a focus on R&D, building a robust pipeline 3. Established innovative drug commercialization platform with a top-notch team and a differentiated approach 4. Strategic business collaborations with selected partners to in-license programs that are synergistic with our pipeline 5. Visionary management supported by a strong team of talents